COCRYSTAL PHARMA INC COCP
COM NEW · Common Stock · CUSIP 19188J409
Company in Bothell, United States
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersBothell, WA
- Websitecocrystalpharma.com
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 10.2m as of 2023-11-13, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $1.87.
Trends to Q3 2023
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2022 | 22 |
| Q1 2023 | 22 |
| Q2 2023 | 21 |
| Q3 2023 | 17 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2023 | 5 | 6 |
| Q2 2023 | 4 | 5 |
| Q3 2023 | 6 | 7 |
Biggest buyers
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Added | +57.3k |
| VANGUARD GROUP INC | Added | +4.2k |
| RENAISSANCE TECHNOLOGIES LLC | Added | +1.7k |
| JPMORGAN CHASE & CO | Added | +1.3k |
| FMR LLC | Added | +96 |
| BANK OF AMERICA CORP /DE/ | Added | +53 |
Biggest sellers
| Parallel Advisors, LLC | Sold out | -15.2k |
| GEODE CAPITAL MANAGEMENT, LLC | Reduced | -9.1k |
| Tower Research Capital LLC (TRC) | Reduced | -2.3k |
| Clean Yield Group | Sold out | -418 |
| UBS Group AG | Sold out | -276 |
| WELLS FARGO & COMPANY/MN | Reduced | -12 |
| OSAIC HOLDINGS, INC. | Sold out | -2 |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
OPKO HEALTH, INC.
13D · may seek influence
new · filed 2026-08-07
Stated purposeOPKO acquired the shares of Common Stock for investment purposes. On July 31, 2026, OPKO and Issuer entered into the Securities Purchase Agreement pursuant to which OPKO purchased $5,000,000 of Common Stock from the Issuer. Dr. Frost and FGIT acquire shares of common stock for investment purposes. Further, in their capacity as directors of the Issuer, Dr. Frost and Mr. Rubin may, from time to time, formulate plans or proposals regarding the Issuer or its securities for consideration by the board of directors of the Issuer and the Issuer's management. OPKO intends to review its investments in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the Issuer's financial position and strategic direction, actions taken by the board of directors, price le… Full filing |
29.6% |
FROST PHILLIP MD ET AL
13D · may seek influence
-3.9 pts · filed 2026-08-07
Stated purposeThe Reporting Persons acquired the shares of common stock for investment purposes. These securities are held by Frost Gamma Investments Trust, of which Phillip Frost, MD is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole shareholder of Frost-Nevada Corporation. Dr. Frost disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of these securities for… Full filing |
13.9% |
Insider purchases and sales in Q3 2023
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q4 2021 | 0 | — | 0 | — | — |
| Q1 2022 | 0 | — | 0 | — | — |
| Q2 2022 | 0 | — | 0 | — | — |
| Q3 2022 | 0 | — | 0 | — | — |
| Q4 2022 | 0 | — | 0 | — | — |
| Q1 2023 | 0 | — | 0 | — | — |
| Q2 2023 | 1 | $2.0m | 0 | — | — |
| Q3 2023 | 0 | — | 0 | — | — |
None reported in Q3 2023.
Holders, Q3 2023
| Manager | Shares | Change |
|---|---|---|
| VANGUARD GROUP INC 0.00% of their portfolio | 275.7k $515.5k | Added +4.2k |
| RENAISSANCE TECHNOLOGIES LLC 0.00% of their portfolio | 126.2k $236.0k | Added +1.7k |
| BlackRock Inc. 0.00% of their portfolio | 74.1k $138.5k | Unchanged |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.00% of their portfolio | 72.2k $135.0k | Added +57.3k |
| GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio | 60.4k $113.0k | Reduced -9.1k |
| MORGAN STANLEY 0.00% of their portfolio | 44.5k $83.1k | Unchanged |
| STATE STREET CORP 0.00% of their portfolio | 24.4k $45.7k | Unchanged |
| NORTHERN TRUST CORP 0.00% of their portfolio | 12.2k $22.8k | Unchanged |
| BANK OF AMERICA CORP /DE/ 0.00% of their portfolio | 9.0k $16.9k | Added +53 |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 3.3k $6.3k | Reduced -2.3k |
| JPMORGAN CHASE & CO 0.00% of their portfolio | 1.7k $3.3k | Added +1.3k |
| FMR LLC 0.00% of their portfolio | 187 $350 | Added +96 |
| WELLS FARGO & COMPANY/MN 0.00% of their portfolio | 89 $166 | Reduced -12 |
| NVWM, LLC 0.00% of their portfolio | 84 $157 | Unchanged |
| Archer Investment Corp 0.00% of their portfolio | 84 $157 | Unchanged |
| ROYAL BANK OF CANADA 0.00% of their portfolio | 9 $0 | Unchanged |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | Unchanged |